# **Intravenous Immunoglobulins Market will reach a value of US$ 15,789.1 Million by 2025 at a CAGR of 6.2%**

The [market for intravenous immunoglobulins](www.fortunebusinessinsights.com/industry-reports/intravenous-immunoglobulins-market-100593) is being stimulated by the rising prevalence of primary immunodeficiency worldwide. Intravenous immunoglobulins: Global Market Analysis, Insights and Forecast, 2018–2025 is the title of a report released by Fortune Business Insights. The report estimates that the global market had a value of **$9,787.6 million** in 2017. By the end of 2025, the market is projected to have grown at a **CAGR of 6.2%** and to be worth **US$15,789.1.**

The report divides the global market by indication into categories such as primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), and others. In 2017, primary immunodeficiency dominated the market. In 2017, the sector represented 28.6% of the global market. The segment is anticipated to grow at an impressive rate between 2018 and 2025.

Intravenous immunoglobulin use is being encouraged by the growing primary immunodeficiency diagnosis rate. Additionally, patients who are unable to administer immunoglobulin to themselves are further driving up demand for intravenous immunoglobulins. In addition, due to the low prevalence of the disease, the chronic inflammatory demyelinating polyneuropathy segment is anticipated to grow more slowly.

**Get Sample PDF Brochure:**  https://www.fortunebusinessinsights.com/enquiry/sample/intravenous-immunoglobulins-market-100593

**Intravenous Immunoglobulin Application in Hospitals to Rise Persistently**

Intravenous immunoglobulin is the most common route of administration of immunoglobulins, which is the chief driver of the global market. The rising demand from hospitals and speciality clinics is anticipated to encourage the adoption of intravenous immunoglobulins. Furthermore, key companies are increasingly investing in the research and development of advanced intravenous immunoglobulins. Such researches are likely to enable growth in the market over the forecast period.

Immunoglobulins are proven to be one of the best treatment options for various immune diseases. Owing to the high popularity of immunoglobulins, the market is foreseen to witness high demand.

On the contrary, factors that may restrain the global intravenous immunoglobulins market are side effects associated with intravenous immunoglobulins and intravenous immunoglobulin’s high cost.

**Key Points Covered in Intravenous Immunoglobulin Market**

* Increasing prevalence of autoimmune and inflammatory disorders: The growing prevalence of autoimmune and inflammatory disorders such as rheumatoid arthritis, multiple sclerosis, and lupus is driving the demand for intravenous immunoglobulin (IVIG) products.
* Advancements in IVIG product development: Pharmaceutical companies are focusing on developing new and improved IVIG products with enhanced efficacy and safety profiles, which is expected to fuel market growth.
* The growing use of IVIG in paediatrics: The increasing use of IVIG in the treatment of pediatric disorders such as primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and Kawasaki disease is expected to drive market growth.
* High cost of IVIG treatment: The high cost of IVIG treatment is a major barrier to market growth, as it can be prohibitively expensive for many patients.
* Grifols S.A., CSL Behring and Shire (Takeda Pharmaceutical Company Limited) are the leading market players in Intravenous Immunoglobulins Market.

**North America to Continue Dominating Global Market**

The North American intravenous immunoglobulins market was worth US$ 5,587.4 Mn in 2017. The region is further expected to emerge dominant over the forecast period. The increasing number of patients in the region is anticipated to drive the regional market. Moreover, in terms of the dominance of route of administration, intravenous (IV) is the most dominating type in developing nations. This is likely to enable growth in the market. Besides this, advanced intravenous immunoglobulins are being rapidly adopted in developed nations.

This in response is fueling the demand in the market. Asia Pacific is anticipated to expand at a promising CAGR. Owing to the high prevalence of primary immunodeficiency in the Asian population, the market is foreseen to witness demand for immunoglobulin.

The competition among the key players is increasing. Owing to the prevailing opportunities, players are focusing on the adoption of innovative strategies to gain a strong brand presence. In 2017 Grifols, S.A. was leading the global market owing to its diverse product portfolio. Grifols, S.A. also holds a major share in the European and North American intravenous immunoglobulins market.

Other key companies operating in the global intravenous immunoglobulins market are CSL Behring, Grifols, S.A., Kedrion S.p.A, Octapharma, Bio Products Laboratory Ltd., Biotest AG, China Biologic Products Holdings, Inc., LFB SA and Shanghai RAAS Blood Products Co., Ltd.

**Speak To Our Analyst:**  https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/intravenous-immunoglobulins-market-100593